Final 4-year results of the RAINBOW real-world study : intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration Article - 2022

Salomon-Yves Cohen, Marcel Dominguez, Florence Coscas, Céline Faure, Stéphanie Baillif, Hassiba Oubraham, Laurent Kodjikian, Michel Weber

Salomon-Yves Cohen, Marcel Dominguez, Florence Coscas, Céline Faure, Stéphanie Baillif, Hassiba Oubraham, Laurent Kodjikian, Michel Weber, « Final 4-year results of the RAINBOW real-world study : intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration  », Graefe’s Archive for Clinical and Experimental Ophthalmology, 2022. ISSN 0721-832X

Abstract

Abstract Purpose The purpose of this study is to evaluate real-world treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) in routine clinical practice in France. Methods RAINBOW (NCT02279537) was an ambispective, observational, 4-year study assessing IVT-AFL effectiveness, treatment patterns, and safety in patients with nAMD in France. Treatment-naïve patients prescribed IVT-AFL and treated according to local practice (pro re nata or treat-and-extend) were eligible. Three treatment cohorts were retrospectively identified based on their treatment pattern within the first 12 months : regular (3 initial monthly IVT-AFL injections received within 45–90 days after the first injection in month 0 and followed by injections every 2 months), irregular with the initial monthly injections, and irregular without the initial monthly injections. The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline to month 12. The 48-month results are described here. Results Overall, the study included 516 patients (each with one study eye), and 30.2% of patients completed 48 months of IVT-AFL treatment. Mean change in BCVA from baseline (56.5 letters) to month 48 for patients with an assessment at both time points was + 1.1 (regular cohort, n = 47), + 0.1 (irregular cohort with initial monthly injections, n = 115), and − 1.3 letters (irregular cohort without initial monthly injections, n = 26), representing a decrease from the gains achieved at month 12. Mean number of IVT-AFL injections received by month 48 in the treatment cohorts was 14.9, 13.7, and 11.9, respectively. The safety profile of IVT-AFL was consistent with previous studies. Conclusion In RAINBOW, the 48-month results demonstrate a lack of long-term effectiveness of IVT-AFL treatment of nAMD due to progressive undertreatment in routine clinical practice in France. These real-world findings highlight the importance of 3 initial monthly IVT-AFL injections followed by continuous proactive treatment beyond the first year to achieve optimal functional outcomes. Trial registration number ClinicalTrials.gov Identifier : NCT02279537.

Voir la notice complète sur HAL

Actualités